SOCRA CCRP Adverse Events 3 — Questions and Answers
Question 1: What is the key difference between 'intensity' and 'causality' when assessing an adverse event?
- They are interchangeable terms for AE grading
- Intensity describes severity (mild/moderate/severe); causality describes the relationship to the study drug (Correct answer)
- Intensity is assessed by FDA; causality by the IRB
- Intensity applies only to SAEs; causality applies to all AEs
Correct answer: Intensity describes severity (mild/moderate/severe); causality describes the relationship to the study drug
Intensity (severity) describes how severe the event is, while causality assesses the likelihood that the event is related to the investigational product.
Question 2: What is 'unmasking' or 'unblinding' in the context of SAE reporting?
- Removing a subject's identifying information from the report
- Revealing the subject's treatment assignment to assess causality for an SAE (Correct answer)
- Publishing SAE data before the trial ends
- Conducting a safety review without the DSMB
Correct answer: Revealing the subject's treatment assignment to assess causality for an SAE
Unblinding for an SAE involves revealing the subject's treatment assignment (active vs. placebo) to allow proper causality assessment while maintaining blind for others.
Question 3: Under 21 CFR 312.32, what is the reporting timeframe for serious, unexpected AEs that are NOT fatal or life-threatening?
- 7 calendar days
- 15 calendar days (Correct answer)
- 30 calendar days
- 45 calendar days
Correct answer: 15 calendar days
Non-fatal, non-life-threatening unexpected serious adverse drug reactions must be reported to the FDA within 15 calendar days under 21 CFR 312.32.
Question 4: What is a 'follow-up report' in the context of adverse event reporting?
- A routine scheduled safety report
- An updated report submitted when new information about a previously reported SAE becomes available (Correct answer)
- A report submitted after a DSMB meeting
- The final summary of all AEs at the end of the trial
Correct answer: An updated report submitted when new information about a previously reported SAE becomes available
A follow-up report is submitted when new information (such as outcome, additional lab results, or revised causality) becomes available for a previously reported expedited SAE.
Question 5: What does 'medical monitoring' of adverse events involve in a clinical trial?
- Scheduling subject medical appointments
- Ongoing review of safety data by a qualified medical professional to detect safety signals (Correct answer)
- Auditing site medical records for accuracy
- Monitoring drug storage temperatures
Correct answer: Ongoing review of safety data by a qualified medical professional to detect safety signals
Medical monitoring involves a sponsor's qualified medical professional continuously reviewing safety data to identify potential safety signals and protect participant safety.
Question 6: What is the purpose of collecting 'concomitant medications' data during a clinical trial?
- To meet billing and reimbursement requirements
- To assess potential drug interactions and confounding effects on safety and efficacy outcomes (Correct answer)
- To ensure subjects follow the prescribed dosing schedule
- To track healthcare utilization costs
Correct answer: To assess potential drug interactions and confounding effects on safety and efficacy outcomes
Collecting concomitant medication data allows detection of potential drug-drug interactions that could confound efficacy results or contribute to observed adverse events.
SOCRA CCRP Adverse Events 3
What is the key difference between 'intensity' and 'causality' when assessing an adverse event?